• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 3 filed by new insider Burkhart Erin

    9/23/25 7:53:59 PM ET
    $GILD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $GILD alert in real time by email
    SEC FORM 3 SEC Form 3
    FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0104
    Estimated average burden
    hours per response: 0.5
    1. Name and Address of Reporting Person*
    Burkhart Erin

    (Last) (First) (Middle)
    333 LAKESIDE DRIVE

    (Street)
    FOSTER CITY CA 94404

    (City) (State) (Zip)
    2. Date of Event Requiring Statement (Month/Day/Year)
    09/22/2025
    3. Issuer Name and Ticker or Trading Symbol
    GILEAD SCIENCES, INC. [ GILD ]
    4. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    Director 10% Owner
    X Officer (give title below) Other (specify below)
    SVP, Controllership
    5. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Beneficially Owned
    1. Title of Security (Instr. 4) 2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 4. Nature of Indirect Beneficial Ownership (Instr. 5)
    Table II - Derivative Securities Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 4) 2. Date Exercisable and Expiration Date (Month/Day/Year) 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 6. Nature of Indirect Beneficial Ownership (Instr. 5)
    Date Exercisable Expiration Date Title Amount or Number of Shares
    Explanation of Responses:
    Remarks:
    No securities are beneficially owned.
    /s/ Edward S. Son by Power of Attorney for Erin E. Burkhart 09/23/2025
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $GILD alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $GILD

    DatePrice TargetRatingAnalyst
    8/19/2025$128.00Neutral → Outperform
    Daiwa Securities
    8/8/2025$127.00Hold → Buy
    Truist
    7/25/2025$133.00Hold → Buy
    Needham
    4/22/2025$125.00Overweight
    Cantor Fitzgerald
    3/4/2025$115.00 → $132.00Outperform
    Oppenheimer
    2/18/2025$120.00Hold → Buy
    Deutsche Bank
    2/13/2025$108.00Hold → Buy
    DZ Bank
    1/10/2025$87.00 → $113.00Equal-Weight → Overweight
    Morgan Stanley
    More analyst ratings

    $GILD
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Gilead to Spotlight New Virology Data Across HIV, Viral Hepatitis and Respiratory Diseases at IDWeek 2025

    – Additional Phase 3 PURPOSE Data Reinforce the Safety Profile of Twice-Yearly Yeztugo® as an Effective HIV Prevention Option Across Diverse Populations – – New Data Show Higher Treatment Satisfaction After Switching from IM CAB+RPV to Biktarvy® – – New Research Reaffirms Veklury® in High-Risk COVID-19 Populations and Obeldesivir in Emerging Pathogens – Gilead Sciences, Inc. (NASDAQ:GILD) will present new findings from its antiviral research and development programs at IDWeek, taking place October 19-22 in Atlanta, GA. Data from 34 presentations across HIV, respiratory viruses, viral hepatitis, and viruses of pandemic potential including six oral presentations underscore Gilead's lead

    10/19/25 8:30:00 AM ET
    $GILD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Trodelvy® Reduces Risk of Disease Progression or Death by 38% Versus Chemotherapy as First-Line Therapy in Patients With Metastatic Triple-Negative Breast Cancer in ASCENT-03 Study

    – Late-Breaking ASCENT-03 Data Simultaneously Presented at ESMO 2025 and Published in The New England Journal of Medicine – – With Two Positive Phase 3 Trials, Trodelvy Has Potential as the First and Only ADC to be a Backbone Standard of Care for All First-Line Metastatic TNBC Patients Regardless of PD-L1 Status – Gilead Sciences, Inc. (NASDAQ:GILD) today shared positive data from the Phase 3 ASCENT-03 study demonstrating a highly statistically significant and clinically meaningful improvement in progression-free survival (PFS) for Trodelvy® (sacituzumab govitecan-hziy) compared to chemotherapy as first-line treatment in patients with metastatic triple-negative breast cancer (TNBC) who

    10/19/25 2:30:00 AM ET
    $GILD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Gilead Presents New HIV Research Data at EACS 2025 – Driving Scientific Innovation in Treatment and Prevention

    – New Data Showcase Safety Profile of Twice-Yearly Lenacapavir for Pre-Exposure Prophylaxis (PrEP) with Other Medications and Recruitment Strategies for PURPOSE 5 – – Five-Year BICSTaR Results Offer Insights into Long-Term Treatment with Biktarvy®, Helping Inform the Future of Coordinated, Person-Centered HIV Care – – Latest Results on Novel Long-Acting Combination Regimens, Including Once-Weekly and Twice-Yearly Treatment Options – Gilead Sciences, Inc. (NASDAQ:GILD) today announced its upcoming participation in the 20th European AIDS Conference (EACS) to be held in Paris, France from October 15-18. As the leader in HIV innovation, Gilead will provide an update on its strategic initi

    10/15/25 3:30:00 AM ET
    $GILD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $GILD
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Gilead Sciences upgraded by Daiwa Securities with a new price target

    Daiwa Securities upgraded Gilead Sciences from Neutral to Outperform and set a new price target of $128.00

    8/19/25 8:30:09 AM ET
    $GILD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Gilead Sciences upgraded by Truist with a new price target

    Truist upgraded Gilead Sciences from Hold to Buy and set a new price target of $127.00

    8/8/25 7:56:58 AM ET
    $GILD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Gilead Sciences upgraded by Needham with a new price target

    Needham upgraded Gilead Sciences from Hold to Buy and set a new price target of $133.00

    7/25/25 8:51:37 AM ET
    $GILD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $GILD
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Gilead Sciences, Inc. converted options into 3,216,119 shares and bought $20,020,000 worth of shares (910,000 units at $22.00) (SEC Form 4)

    4 - GILEAD SCIENCES, INC. (0000882095) (Reporting)

    2/13/24 5:48:49 PM ET
    $GILD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $GILD
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for SUNLENCA issued to GILEAD SCIENCES INC

    Submission status for GILEAD SCIENCES INC's drug SUNLENCA (SUPPL-6) with active ingredient LENACAPAVIR SODIUM has changed to 'Approval' on 11/25/2024. Application Category: NDA, Application Number: 215973, Application Classification: Efficacy

    11/26/24 4:36:21 AM ET
    $GILD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    FDA Approval for SUNLENCA issued to GILEAD SCIENCES INC

    Submission status for GILEAD SCIENCES INC's drug SUNLENCA (SUPPL-8) with active ingredient LENACAPAVIR SODIUM has changed to 'Approval' on 11/25/2024. Application Category: NDA, Application Number: 215974, Application Classification: Efficacy

    11/26/24 4:36:21 AM ET
    $GILD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    FDA Approval for SUNLENCA issued to GILEAD SCIENCES INC

    Submission status for GILEAD SCIENCES INC's drug SUNLENCA (SUPPL-9) with active ingredient LENACAPAVIR SODIUM has changed to 'Approval' on 11/13/2024. Application Category: NDA, Application Number: 215973, Application Classification: Manufacturing (CMC)

    11/15/24 4:36:27 AM ET
    $GILD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $GILD
    SEC Filings

    View All

    Gilead Sciences Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - GILEAD SCIENCES, INC. (0000882095) (Filer)

    10/6/25 8:17:11 AM ET
    $GILD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 144 filed by Gilead Sciences Inc.

    144 - GILEAD SCIENCES, INC. (0000882095) (Subject)

    9/15/25 4:04:03 PM ET
    $GILD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form N-PX filed by Gilead Sciences Inc.

    N-PX - GILEAD SCIENCES, INC. (0000882095) (Filer)

    8/29/25 10:09:00 AM ET
    $GILD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $GILD
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Financial Officer Dickinson Andrew D sold $295,200 worth of shares (2,500 units at $118.08), decreasing direct ownership by 2% to 157,055 units (SEC Form 4)

    4 - GILEAD SCIENCES, INC. (0000882095) (Issuer)

    10/16/25 9:35:03 PM ET
    $GILD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Chief Commercial Officer Mercier Johanna sold $354,240 worth of shares (3,000 units at $118.08), decreasing direct ownership by 3% to 110,193 units (SEC Form 4)

    4 - GILEAD SCIENCES, INC. (0000882095) (Issuer)

    10/16/25 9:28:28 PM ET
    $GILD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Chairman & CEO O'Day Daniel Patrick sold $1,116,564 worth of shares (10,000 units at $111.66), decreasing direct ownership by 2% to 591,203 units (SEC Form 4)

    4 - GILEAD SCIENCES, INC. (0000882095) (Issuer)

    9/30/25 4:57:47 PM ET
    $GILD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $GILD
    Financials

    Live finance-specific insights

    View All

    Gilead to Spotlight New Virology Data Across HIV, Viral Hepatitis and Respiratory Diseases at IDWeek 2025

    – Additional Phase 3 PURPOSE Data Reinforce the Safety Profile of Twice-Yearly Yeztugo® as an Effective HIV Prevention Option Across Diverse Populations – – New Data Show Higher Treatment Satisfaction After Switching from IM CAB+RPV to Biktarvy® – – New Research Reaffirms Veklury® in High-Risk COVID-19 Populations and Obeldesivir in Emerging Pathogens – Gilead Sciences, Inc. (NASDAQ:GILD) will present new findings from its antiviral research and development programs at IDWeek, taking place October 19-22 in Atlanta, GA. Data from 34 presentations across HIV, respiratory viruses, viral hepatitis, and viruses of pandemic potential including six oral presentations underscore Gilead's lead

    10/19/25 8:30:00 AM ET
    $GILD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Gilead Presents New HIV Research Data at EACS 2025 – Driving Scientific Innovation in Treatment and Prevention

    – New Data Showcase Safety Profile of Twice-Yearly Lenacapavir for Pre-Exposure Prophylaxis (PrEP) with Other Medications and Recruitment Strategies for PURPOSE 5 – – Five-Year BICSTaR Results Offer Insights into Long-Term Treatment with Biktarvy®, Helping Inform the Future of Coordinated, Person-Centered HIV Care – – Latest Results on Novel Long-Acting Combination Regimens, Including Once-Weekly and Twice-Yearly Treatment Options – Gilead Sciences, Inc. (NASDAQ:GILD) today announced its upcoming participation in the 20th European AIDS Conference (EACS) to be held in Paris, France from October 15-18. As the leader in HIV innovation, Gilead will provide an update on its strategic initi

    10/15/25 3:30:00 AM ET
    $GILD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Gilead Sciences to Release Third Quarter 2025 Financial Results on Thursday, October 30, 2025

    Gilead Sciences, Inc. (NASDAQ:GILD) announced today that its third quarter 2025 financial results and guidance will be released on Thursday, October 30, 2025 after the market closes. At 4:30 p.m. Eastern Time that day, Gilead's management will host a webcast to discuss the company's third quarter 2025 financial results and provide a business update. A live webcast will be available in the Investors section of www.gilead.com and will be archived there for one year. About Gilead Sciences Gilead Sciences, Inc. is a biopharmaceutical company that has pursued and achieved breakthroughs in medicine for more than three decades, with the goal of creating a healthier world for all people. The

    10/9/25 4:05:00 PM ET
    $GILD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $GILD
    Leadership Updates

    Live Leadership Updates

    View All

    Contineum Therapeutics Appoints Timothy Watkins, M.D., M.Sc., as Chief Medical Officer and Head of Development

    Contineum Therapeutics, Inc. (NASDAQ:CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated therapies for the treatment of neuroscience, inflammation and immunology (NI&I) indications, today announced the appointment of Timothy Watkins, M.D., M.Sc., to the Company's executive team as its Chief Medical Officer and Head of Development. Effective immediately, Dr. Watkins will lead all clinical development and medical affairs activities at Contineum. Dr. Watkins succeeds Stephen L. Huhn, M.D., who has been the Company's Chief Medical Officer since early 2020. Dr. Huhn will serve as an advisor during the leadership transition. "We're excited for D

    4/28/25 4:05:00 PM ET
    $CTNM
    $GILD
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)

    Gilead Sciences Appoints Dietmar Berger, MD, PhD, as Chief Medical Officer

    Gilead Sciences, Inc. (NASDAQ:GILD) today announced that Dietmar Berger, MD, PhD, will join the company on January 2, 2025, as Chief Medical Officer and will become a member of Gilead's senior leadership team. Dr. Berger succeeds Merdad Parsey, MD, PhD. Dr. Berger is a board-certified internist, hematologist and oncologist who brings more than 25 years of extensive experience in developing and delivering innovative medicines across a broad range of therapeutic areas. He will assume responsibility for the Company's leading virology, oncology and inflammation portfolio and will oversee the company's global Development and Medical Affairs organizations. "Dietmar's exceptional leadership in

    12/12/24 5:30:00 PM ET
    $GILD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Galapagos appoints Thad Huston as Chief Financial Officer and Chief Operating Officer

    Mechelen, Belgium; 15 June 2023, 22:01 CET; regulated information – Galapagos NV ((Euronext &, NASDAQ:GLPG) today announced the appointment of Thad Huston as Chief Financial Officer (CFO) and Chief Operating Officer (COO) as per 1 July 2023. Mr. Huston will be a member of the Executive Committee of Galapagos and will join Galapagos from Kite, a Gilead Company (NASDAQ:GILD). He brings 30 years of global finance and operational experience in healthcare with an excellent track record of driving business transformation and innovation. "On behalf of the Board of Directors and management of Galapagos, I extend a warm welcome to Thad. Thad is a widely recognized leader with a strong internationa

    6/15/23 4:01:00 PM ET
    $GILD
    $GLPG
    $JNJ
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Biotechnology: Electromedical & Electrotherapeutic Apparatus

    $GILD
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Gilead Sciences Inc. (Amendment)

    SC 13G/A - GILEAD SCIENCES, INC. (0000882095) (Subject)

    2/9/24 6:21:28 PM ET
    $GILD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G/A filed by Gilead Sciences Inc. (Amendment)

    SC 13G/A - GILEAD SCIENCES, INC. (0000882095) (Subject)

    2/13/23 3:32:27 PM ET
    $GILD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G filed by Gilead Sciences Inc.

    SC 13G - GILEAD SCIENCES, INC. (0000882095) (Subject)

    2/13/23 2:49:26 PM ET
    $GILD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care